Treatment effectiveness and side effects: A model of physician learning

Management Science

Volumn 59, Issue 6, 2013, Pages 1309-1325

  Chan, Tat ^a   Narasimhan, Chakravarthi ^a   Xie, Ying ^b  

^a WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Advertising; Multiple dimensional learning; New product; Pharmaceutical marketing

Indexed keywords

ERECTILE DYSFUNCTION; MULTIPLE-DIMENSIONAL LEARNING; NEW ENTRANTS; NEW PRODUCT; PHARMACEUTICAL MARKETING; SIDE EFFECT;

MARKETING; PATIENT TREATMENT;

DRUG INTERACTIONS;

EID: 84878988906     PISSN: 00251909     EISSN: 15265501     Source Type: Journal    
DOI: 10.1287/mnsc.1120.1640     Document Type: Article

References (31)

1. Ackerberg D (2001) Empirically distinguishing informative and prestige effects of advertising. RAND J. Econom. 32(2):316-333.
2. Berry S, Levinsohn J, Pakes A (2004) Differentiated products demand systems from a combination of micro and macro data: The new vehicle market. J. Political Econom. 112(1):68-104.
3. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S (2002) Efficacy and safety of Tadalafil for the treatment of erectile dysfunction: Results of integrated analysis. J. Urology 168(4):1332-1336.
4. Chan T, Hamilton B (2006) Learning, private information and the economic evaluation of randomized experiments. J. Political Econom. 115(6):997-1040.
5. Ching A (2010) Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration. Internat. J. Indust. Organ. 28(6):619-638.
6. Ching A, Ishihara M (2010) The effects of detailing on prescribing decisions under quality uncertainty. Qualitative Marketing Econom. 8(2):123-165.
7. Ching A, Ishihara M (2012) Measuring the informative and persuasive roles of detailing on prescribing decisions. Management Sci. 58(7):1374-1387.
8. Chintagunta PK, Renna J, Ginger ZJ (2009) Information, learning, and drug diffusion: The case of Cox-2 inhibitors. Quant. Marketing Econom. 7(4):399-443.
9. Crawford G, Shum M (2005) Uncertainty and learning in pharmaceutical demand. Econometrica 73(4):1137-1174.
10. DeGroot MH (1970) Optimal Statistical Decisions (McGraw-Hill, New York).
11. Dickstein MJ (2011) Efficient provision of experience goods: Evidence from antidepressant choice. Working paper, Stanford University, Stanford, CA.
12. DoganoMglu T (2010) Switching costs, experience goods and dynamic price competition. Quant. Marketing Econom. 8(2):167-205.
13. Erdem T, Keane M (1996) Decision-making under uncertainty: Capturing dynamic brand choice process in turbulent consumer goods markets. Marketing Sci. 15(1):1-20.
14. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral Sildenafil in the treatment of erectile dysfunction. New England J. Medicine 338(20):1397-1404.
15. Harris K, Keane M (1999) A model of health plan choice: Inferring preferences and perceptions from a combination of revealed preference and attitudinal data. J. Econometrics 89(4):614-157.
16. Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H (2002) Vardenafil for treatment of mean with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J. Andrology 23(6):763-771.
17. Hurwitz MA, Caves RE (1988) Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals. J. Law Econom. 31(2):299-320.
18. Klemperer P (1987) Markets with consumer switching costs. Quart. J. Econom. 102(2):375-394.
19. Klemperer P (1988)Welfare effects of entry into market with switching costs. J. Indust. Econom. 37(2):159-165.
20. Klemperer P (1992) Multi-period competition with switching costs. Econometrica 60(3):651-666.
21. Klemperer P (1995) Competition when consumers have switching costs: An overview with applications to industrial organization, macroeconomics, and international trade. Rev. Econom. Stud. 62(4):515-539.
22. Lasser K, Allen P, Woolhandler S, Himmelstein D, Wolfe S, Bor D (2002) Timing of new black box warnings and withdrawals for prescription medications. J. Amer. Medical Assoc. 287(17):2215-2220.
23. Leffler KB (1981) Persuasion or information? The economics of prescription drug advertising. J. Law Econom. 24(1):45-74.
24. Manchanda P, Rossi PE, Chintagunta PK (2004) Response modeling with nonrandom marketing-mix variables. J. Marketing Res. 41(4):467-478.
25. Manchanda P, Xie Y, Youn N (2008) The role of targeted communication and contagion in product adoption. Marketing Sci. 27(6):961-976.
26. Manski C (2004) Measuring expectations. Econometrica 72(5): 1329-1376.
27. Narayanan S, Manchanda P (2009) Heterogeneous learning and the targeting of marketing communication for new products. Marketing Sci. 28(3):424-441.
28. Train K (2003) Discrete Choice Methods with Simulation (Cambridge University Press, Cambridge, UK).
29. Villas-Boas JM (2004) Consumer learning, brand loyalty, and competition. Marketing Sci. 23(1):134-145.
30. Villas-Boas JM (2006) Dynamic competition with experience goods. J. Econom. Management Strategy 15(1):37-66.
31. Villas-Boas JM, Winer RS (1999) Endogeneity in brand choice models. Management Sci. 45(10):1324-1338.